Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study

Paolo A. Ascierto, Claudia Trojaniello, Vanna Chiarion‐Sileni et al.|Frontiers in Oncology|2023

Cited by 3